-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GBI learned that, recently, Beihai Kangcheng Pharmaceutical Co.
At the same time, Beihai Kangcheng also obtained the exclusive right to authorize LB-001 in the Greater China region (including Mainland China, Taiwan, Hong Kong and Macau).
According to the terms of the agreement, LogicBio can obtain a global exclusive authorization prepayment of US$10 million, a maximum of US$564 million in clinical development and commercial milestone payments, and a maximum double-digit royalties based on net sales.
LogicBio Therapeutics is a clinical-stage gene therapy company that develops gene delivery and editing platform technologies.
LogicBio's leading sAAVy capsid development platform is designed to support the development of therapies for the treatment of multiple indications and tissue diseases.